Sherbet Eric sold (to issuer) $1.1M of IQV

Sherbet Eric (See Remarks) sold (to issuer) 3,990 shares of IQVIA HOLDINGS INC. (IQV) at $278.74 ($1.11M total) on 2026-11-09.

Original reporting
SEC EDGAR · Sherbet Eric
Published Nov 13, 2026, 12:42 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 12:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IQV
Neutral
medium confidence
Mentioned
$IQV
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVNeutralLow
01

Why it matters

The disclosed sale is modest but provides a data point for assessing insider sentiment.

02

Market read

A routine insider sale with limited material impact; useful for short‑term sentiment monitoring.

03

What to watch

Potential upcoming corporate actions or compensation plans not disclosed could contextualize the sale.

Relevance 6/10Novelty 3/10Timing: after-hours filing

Background

SEC Form 4 filings disclose insider transactions; traders monitor them for signals about company outlook.

Company-level read

Ticker impact

$IQVNeutralMedium confidence
Context

Officer Sherbet Eric sold 3,990 IQV shares for $1.1M on 2026-11-09, reducing his holding to 20,999 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

The sale size is modest relative to market cap, but insider disposition is a tradable signal.

Market effects

Minimal impact on the healthcare data services sector; no broader trend indicated.

U.S. market only; no regional ripple effect.

Low; the filing is company‑specific and does not affect global markets.

Counterpoint

The sale could be unrelated to confidence and merely a liquidity need; price may remain unchanged.

Key entities

  • IQVIA Holdings Inc.

    U.S.-listed provider of health information technology and data analytics.

  • Sherbet Eric

    Company officer who reported the insider sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IQVHighAI 8/10

5 revealing analyst questions from IQVIA’s Q3 earnings call

IQVIA reported Q3 revenue of $4.43 billion, beating estimates by 1.5%, with adjusted EPS of $3.34, a 2% beat. The company raised full-year revenue guidance to $17.43 billion. Analysts discussed AI-driven workflows, margin improvements, and clinical bookings during the earnings call. CEO Ari Bousbib highlighted proprietary data and life sciences expertise as key differentiators.

$IQVMedAI 8/10

IQVIA Holdings Inc (IQV) (Q3 2026) Earnings Call Highlights: Record Bookings, Raised

IQVIA Holdings Inc. reported Q3 2026 earnings with record bookings and raised guidance. Revenue was $4.428B, up 8% YoY, and adjusted EBITDA rose 8.7%. Challenges include FX headwinds and R&D backlog adjustments. Management highlighted AI adoption and strong biotech demand. Full-year 2026 guidance was increased, with revenue expected between $17.35B-$17.5B. No 2027 guidance was provided.

$IQVHighAI 8/10

What IQVIA (IQV) Said on Its Q3 Earnings Call

IQVIA reported Q3 revenue growth of 6.9% to $1.79B, with organic growth at 4%. AI adoption contributed to commercial and clinical momentum, with 415 AI agents deployed. The company raised its 2026 outlook, expecting revenue of $17.35B-$17.50B and adjusted EPS of $12.90-$13.00. Cash flow from operations was $825M, with free cash flow at $667M.

$IQVHighAI 9/10

IQVIA (IQV) Q3 2026 Earnings Call Transcript

IQVIA reported Q3 2026 revenue of $4.43B, up 8%, with organic growth at 6%. Adjusted EBITDA grew 8.7% to $1.03B, and adjusted EPS rose 11.3% to $3.34. R&D solutions revenue increased 8.7%, and commercial solutions revenue grew 6.9%. The company raised full-year revenue guidance to $17.35B-$17.5B. AI deployments and emerging biopharma funding growth were highlighted.